- Home
- EAD vs BDTX Comparison
EAD vs BDTX Comparison
Compare EAD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | BDTX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 116.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EAD | BDTX |
|---|---|---|
| Price | $6.51 | $2.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 159.5K | ★ 607.9K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.89 | $1.20 |
| 52 Week High | $7.18 | $4.94 |
Technical Indicators
Market Signals| Indicator | EAD | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.52 | 43.75 |
| Support Level | N/A | $1.93 |
| Resistance Level | $6.91 | $2.86 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 13.89 | 38.39 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.